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ABSTRACT 31 
The adenosine triphosphate (ATP) binding-cassette (ABC) transporters are a superfamily 32 
of cellular proteins that have been partly implicated as a cause of multidrug resistance 33 
(MDR) in cancer cells.  The ABC superfamily consists of P-glycoprotein, multidrug 34 
resistance-associated proteins (MRP) and breast cancer-related proteins, of which MRP is 35 
of particular interest because of its ability to efflux a broader range of substrates.  Since 36 
MRP1 is the most prominent member of the MRP family, a simple technique is needed 37 
for its quantification.  We developed a simple, fast (total analysis time of 3 h) capillary 38 
electrophoresis immunoassay (CEIA) for the quantification of MRP1 in cancer cells.  39 
MRP1 antibody was labeled with fluorescein isothiocyanate.  The labeled antibody was 40 
incubated with the cell lysate for a fixed interval (1 h), after which the cell lysate mixture 41 
was directly injected into the capillary to separate the complex of MRP1 and its antibody 42 
from free antibody.  The noncompetitive CEIA method had a limit of detection of 0.1 0.2 43 
nM and a good linear range (1.7 - 14.9 x 104 cells), and was fairly reproducible (RSD < 44 
10%).  The results showed that two cell lines, A549 and RDES, expressed MRP1 in the 45 
absence of doxorubicin (DOX), with A549 registering a higher expression.  The amount 46 
of MRP1 increased after treatment with DOX for 12 h and was constant until 24 h.  The 47 
intracellular accumulation of DOX in cells decreased as the expression of MRP1 48 
increased due to exposure of the cells to DOX, suggesting that the accelerated expression 49 
of MRP1 is responsible for the decrease of DOX in the cells.  Compared to DOX-free 50 
cancer cells, there was an acceleration of MRP1 expression during the 12 h-exposure to 51 
DOX, after which the level of expression remained nearly constant as the intracellular 52 
accumulation of DOX decreased.  The results obtained in this work indicate that the 53 
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developed CEIA method is useful for relative quantification of MRPs in the study on 54 
MDR in of cancer cells. 55 
 56 
1. Introduction 57 
     Chemotherapy treatment of many types of cancers is rendered ineffective due to 58 
intrinsic or acquired multidrug resistance (MDR), which is partly induced by multidrug 59 
transporter proteins such as the adenosine triphosphate (ATP) binding-cassette (ABC) 60 
and lung resistance-related proteins [1-3].  These multidrug transporter proteins actively 61 
efflux drugs out of the cells, thereby reducing their intracellular concentration and leading 62 
to multidrug resistance.  The ABC superfamily constitutes the bulk of the multidrug 63 
transporter proteins, and consists of three main families: multidrug resistance-associated 64 
protein (MRP), P-glycoprotein, and breast cancer-related proteins [1].  Although it has 65 
been less thoroughly investigated than P-glycoprotein, MRP can efflux not only cationic 66 
and neutral hydrophobic compounds, but also anionic conjugates of sulfates, glutathione, 67 
and glucuronic acid.  MRP is made up of several subfamilies including MRP1, MRP2, 68 
MRP3, MRP4, and MRP5.  Because of the role of MPR1 in conferring MDR in tumors 69 
[4], along with its wide occurrence in the human body, its quantification of MRP1 is 70 
extremely important. 71 
   Absolute and relative quantification of the protein transporters has been reported. 72 
While absolute quantification of these transporter proteins is most useful, it is difficult, 73 
time consuming, and expensive, primarily because standards must be synthesized, 74 
purified, and identified prior to quantification by one of the analytical methods, e.g., 75 
HPLC [5,6].  Most methods, however, are based on relative quantification, in which the 76 
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proteins are analyzed by various techniques without using standards.  Methods of 77 
transporter protein quantification that have been studied include PCR [7-9] (RT-PCR, 78 
real time RT-PCR), Western blotting [10,11], flow cytometry [12,13], and 79 
electrochemical immunoassay [14].  Western blotting is not only semi-quantitative, but 80 
also time consuming, and requires large sample sizes.  The main disadvantages of flow 81 
cytometry are its expensive instrumentation and difficulty in the determination of 82 
transporter proteins localized at cell organelles, since flow cytometry only measures the 83 
transporter proteins located at the cell surface.  PCR techniques require a longer analysis 84 
time for separation, detection, and accurate quantification, and may suffer from 85 
contamination of the probe, which may lead to false positives [15].  86 
Although ABC transporter proteins are generally thought to mediate drug efflux at the 87 
plasma membrane [16-18], some studies have shown that these proteins are localized in 88 
cell organelles like the nucleus [19,20].  Because the transporter proteins could be 89 
localized anywhere in the cells, it is more useful to determine the total intracellular 90 
amount of the transporter protein after carrying out cell lysis.  Such determinations are 91 
more suitably carried out by capillary electrophoresis immunoassay (CEIA).  Indeed 92 
CEIA may address some of the shortcomings of the established methods requires 93 
antibody, like other assays such as ELISA, Western blotting, and flow cytometry because 94 
it is easy to automate, requires smaller sample sizes and shorter analysis time, has simple 95 
procedures, and is capable of multi-analyte analysis [21].  CEIA in either competitive [22, 96 
23] or noncompetitive [24] formats, may utilize antibody [22], enzymes [25] or aptamers 97 
[26,27] as ligand to interact with antigens to form complexes in highly complicated 98 
matrices. address some of the aforementioned shortcomings of these established methods.  99 
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While Since the pioneering works by Nielsen et al. [28], CEIA has found application in 100 
the determination of wide range of analytes including toxins [29], drugs and metabolites 101 
[30], hormones [31], peptides [32], and proteins [33].  While most CEIA investigations of 102 
proteins have focused on lower molecular weight proteins (10 - 80 kD), reports on the 103 
determination of higher molecular weight proteins, like ABC transporter proteins (170-104 
190 kD) in cells are few.  It is worth noting that even CEIA reports of the most 105 
extensively studied ABC transporter-protein, P-glycoprotein, are rare.  106 
     In the present study, a simple, non-competitive CEIA method for the relative 107 
quantification of MRP1 was developed.  Laser-induced fluorescence (LIF) was used for 108 
detection of the transporter protein in order to solve the problem of low sensitivity 109 
inherent in the capillary electrophoresis (CE) technique.  Since baseline resolution of 110 
complex and antibody is necessary for this method, antibody instead of enzymes or 111 
aptamers was employed because the smaller size of the two ligands will lead to poor 112 
resolution between the complex and free ligand for bulky proteins such as MRP1.  The 113 
method involved reacting cell lysate with an excess of the labeled anti-MRP1 antibody 114 
and adding an internal standard, followed by immediate injection of the unincubated 115 
mixture into the CE system to obtain the antibody peak before the immunological 116 
reaction.  After two or three swift, consecutive runs, the cell lysate mixture was incubated, 117 
after which more CE runs were made to obtain peaks for the free antibody and formed 118 
immune complex.  The amount of the formed immune complex was used to determine 119 
the amount of protein contained in the cell lysate.  It should be noted that no purification 120 
of the antibody was necessary, as quantification of the protein is based on the immune 121 
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complex and not the post-incubation amount of the antibody.  This method was used to 122 
compare the levels of MRP1 expressed in cancer cells A549 and RDES.  123 
 124 
2. Materials and methods 125 
2.1. Materials 126 
     Sodium tetraborate decahydrate, glycine, tricine, doxorubicin (DOX, in hydrochloride 127 
form), absolute ethanol, rhodamine B, hydrochloric acid, sodium fluorescein, and Tris 128 
were purchased from Wako Pure Chemicals (Osaka, Japan).  Monoclonal anti-MRP1 129 
(Clone QCRL-4, Purified Mouse Immunoglobulin, Product Number M9192), sodium 130 
dodecylsulfate (SDS - electrophoresis grade), sodium taurodeoxycholate (STDC) hydrate, 131 
and (2-hydroxypropyl)-γ-cyclodextrin, were obtained from Sigma Aldrich (St. Louis, MO, 132 
USA).  A Fluorescein Labeling Kit-NH2 and EDTA were obtained from Dojindo 133 
(Kumamoto, Japan).  Sodium chloride was obtained from Chameleon Reagents (Osaka, 134 
Japan).  A bicinchoninic acid (BCA) protein assay kit was purchased from Pierce 135 
Biotechnology (Rockford, IL, USA).  Lung cancer cells, A549, were purchased from the 136 
Health Science Research Resources Bank (Osaka, Japan).  Human Ewing’s family tumor 137 
cell line (RDES) was obtained from the American Type Culture Collection (VA, USA).   138 
   Stock solutions of Tripsintrypsin-EDTA (0.05%), RPMI and DMEM media, and 139 
DPBS (1X) were purchased from Invitrogen (Grand Island, NY, USA).  All solutions 140 
were prepared in pure 18-MΩ MilliQ water (Millipore SA, Molsheim, France).  A stock 141 
solution of DOX (200 μM) was prepared in MilliQ water, stored in opaque containers and 142 
kept refrigerated at 4 oC.  The migrationng solution consisted of sodium tetraborate (120 143 
mM of borate), glycine (50 mM), and tricine (50 mM) adjusted to pH 8.9.  The 144 
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preparation of the migrationng solution for DOX measurement and the cell lysis buffer 145 
has been described elsewhere [34]. 146 
 147 
2.2. Treatment of cells with DOX 148 
     Prior to treatment with DOX for a fixed time interval (12 h or 24 h), the cells (A549 or 149 
RDES) were washed thrice with DPBS and separated into 3.5-cm petri dishes.  The cells 150 
in the dishes were cultured until the population they covered 90-100% of the bottom 151 
surface area of the dish.  Thereafter, fresh culture media with and without DOX were 152 
added to the dishes to prepare DOX-free and DOX-treated (500 nM) cells.  After addition 153 
of the appropriate culture medium, the cells were incubated at 37 oC in 5% CO2 for either 154 
12 h or 24 h.  Subsequently, the cells were lifted by adding 200 μL of Tripsintrypsin-155 
EDTA, suspended by adding 800 μL of DPBS, and then transferred into a microvial, 156 
where they were washed (twice or thrice) with DPBS, before addition of the cell lysis 157 
buffer (400 μL).  The cell lysis buffer contains 100 mM NaCl, 20 mM EDTA, 1%(w/v) 158 
SDS and 50 mM Tris-HCl (pH 8).  The treatment of cells to obtain lysate and 159 
measurement of the total protein content were described earlier [34].  Briefly, the lysis 160 
buffer was added to the cells in the microvial.  The solution was vortexed to enhance lysis 161 
and to make the cell lysate uniform.  After complete dissolution of the cells, the cell 162 
lysate was sonicated for about 15 minutes to assist in breaking the long DNA strands, 163 
which results in a uniform cell lysate of lower viscosity.  The obtained cell lysate was 164 
used for antibody binding and protein determination experiments. 165 
 166 
 167 
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2.3 Reaction of cell lysate with antibody 168 
     The antibody was labeled with flourescein according to the labeling kit manufacturer’s 169 
instructions (Dojindo, Kumamoto).  The concentration of the labeled antibody was then 170 
determined by spectroscopic measurement at 280 and 500 nm.  The number of 171 
fluorescein molecules tagged with antibody was also calculated according to the labeling 172 
kit manufacturer’s instructions, using absorbance at 280 and 500 nm.  The number was 173 
calculated to be 5~7 depending on the concentration ratio of the labeling reagent to the 174 
antibody.  However, the antibodies tagged with different numbers of fluorescein molecule 175 
did not show any difference in the immunological reaction.  Therefore, the labeled 176 
antibody tagged with 5~7 fluorescein molecules were directly employed for the 177 
immunoassay. 178 
     In the immunological reaction, a A known excess amount of the labeled antibody (30 179 
nM) was added to 60 μL of the sample, followed by the sodium fluorescein (0.125 μM ) 180 
as internal standard and enough 1x PBS buffer to make 100 μL.  Two or three CE-LIF 181 
runs were made quickly, before the cell lysate mixture was incubated at 37 oC for 1 h, 182 
after which the mixture was directly injected into the capillary for separation by CE-LIF 183 
measurement.   184 
 185 
2.4. CE-LIF measurement 186 
     The CE-LIF system used was described previously [34].  Briefly, a custom-made 187 
system was assembled in a room with a constant temperature (25 oC).  Ordinary fused 188 
silica capillaries (50 μm i.d.; 356 μm o.d.; effective length, 30 cm; total length, 40 cm; 189 
GL Sciences, Tokyo, Japan) were used in the CE-LIF system.  Samples were 190 
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hydrodynamically injected into the capillary for 10 s by siphoning (the sample vial raised 191 
5 cm above the outlet vial), and a separating voltage (10 kV or 15 kV) was applied using 192 
a high voltage power supply (HCZE-30PN0.25, Matsusada Precision Inc, Shiga, Japan).  193 
The LIF detection was done using a 488 nm line of an argon ion laser (Stabilite 2017, 194 
Spectra-Physics, Inc., CA, USA) as the excitation source.  The generated fluorescence 195 
was filtered with a notch filter (Edmund Optics Japan, 46564-K, Tokyo, Japan) and 196 
collected by a photomultiplier tube (model R3896, Hamamatsu, Shizuoka, Japan) biased 197 
at 650 V.  The data generated were processed using an in-house Labview program 198 
(National Instruments, Austin, TX, USA).  The capillary was flushed after every two runs 199 
with NaOH (0.1 M) and migrationng solution for four minutes 4 min each. 200 
 201 
2.5. Data processing 202 
     Pre-incubation electrophoretic measurements were made to determine the peak area 203 
corresponding to the initial amount of the antibody (Aab,0) and the internal standard (AIS-204 
pre).  Post-incubation electrophoretic measurements yielded the peak area corresponding 205 
to the complex (Acomp) and the internal standard (AIS-post).  The peak areas were 206 
proportional to the concentrations of the corresponding species.  Thus, (eq 1), as follows: 207 
 
post-IS
comp
comp
pre-IS
ab,0
ab,0   
A
A
C
A
A
C =      (1) 208 
where Cab,0 and Ccomp represented the initial concentration of antibody and the 209 
concentration of complex produced, respectively.   210 
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Assuming that Under the condition where excess amounts of antibody was added, the 211 
complex was formed  consisted of by one antibody and two one antigen molecules and 212 
the concentration of MRP1 was directly calculated according to eq 2 as follows: 213 
 post-IS
comp
pre-IS
ab,0
ab,0
MRP1        A
A
A
A
C
C ×=   (2) 214 
To correct the concentration of CMRP1 for the number of cells, CMRP1 was divided by 215 
concentration of protein CProtein denoted by the amount of total protein P (mg mL-1) (eq 3), 216 
as follows: 217 
 P
A
A
A
A
C
C
C
otein
MRP
post-IS
comp
pre-IS
ab
ab
Pr
1
     
   
×
=  (3) 218 
Using eq 3 allowed for direct comparison of the MRP1 expressions in the cell lysate. 219 
Using eq 3, simple, direct comparison of  MRP1 expression in cell lysate is readily 220 
accomplished as compared to the more difficult and expensive determination of  absolute  221 
amounts. 222 
 223 
3. Results and discussion 224 
3.1 Method development and kinetics of the complex formation 225 
     Noncompetitive CEIA was adopted because of the lack scarcity of transporter proteins 226 
standards (commercial or synthesized) for the.  Cell lysates of A549 were employed as 227 
samples for optimization of the separation conditions, since it is known that A549 228 
inherently expresses MRP1 [35].  Several migrationng buffers were tested, including 229 
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borate (pH 9), MES (pH 7), HEPES (pH 8), CAPS (pH 9.5), and Tris (pH 8.1), but the 230 
borate buffer showed the best separation of the antibody and its complex.  To control 231 
adsorption of both the antibody and the complex on ordinary silica capillary walls, 232 
Zwitter ionic additives (glycine, tricine) were examined.  Borate-glycine (pH 9.0) 233 
produced inferior resolution of the two peaks, while borate-tricine exhibited improved 234 
peak resolution but suffered peak tailing.  Thus, the two Zwitter ions were combined to 235 
make the migrationng solution of 50 mM glycine and 50 mM tricine in 120 mM borate 236 
buffer (pH 8.9).  Variable concentrations (40 mM-150mM) of the borate buffer were 237 
examined and the optimum concentration was found to be 120 mM.  The applied voltage 238 
was optimized to 10 kV to simultaneously maintain the current below 50 μA and the 239 
resolution between the antibody and the complex. 240 
     The incubation time for antibody-MRP1 complexation was determined by injecting 241 
the mixture of A549 cell lysate and anti-MRP1 at 10 min intervals for a total duration of 242 
73 min.  During this period, the mixture was incubated at 37 oC and sample was directly 243 
injected into the capillary. The mixture was incubated at 37 oC after the first injection of 244 
the mixture into the capillary (0 min).  Fig. 1 shows the progression of complex formation 245 
as the complex peak became increasingly prominent.  As seen in Fig. 1, the complex peak 246 
appeared only when the cell lysate was mixed with anti-MRP1 followed by incubation.  247 
Therefore, the new peak was definitely assigned to the complex.  Fig. 2 shows illustrates 248 
the relationship between reaction time and the relative peak area of the complex.  The 249 
curve in Fig. 2 shows that complex formation was rapid during the first 10 - 15 min and 250 
was nearly complete after about 50 min.  This method can, therefore, be used for kinetic 251 
investigation of antibody-antigen interaction, as it is possible to directly inject the sample 252 
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into the capillary at fixed time intervals (Δt > 10 min) as incubation proceeds.  Based on 253 
the results in Fig. 2, an incubation time of 60 min was adopted, as the peak area remained 254 
nearly constant after 60 min.  Although Wang et al. [36] reported improved stability of 255 
the complex upon addition of BSA into the cell lysate before adding the antibody, no 256 
effect on the stability of either the complex or antibody was observed in this work. 257 
      Although the incubation time of 60 min seems to be long for a reaction in a free 258 
solution, the kinetics of an immunological reaction is not necessarily fast even in the free 259 
solution and is dependent on the type of a target protein.  For example, the incubation 260 
time of insulin antibody was only 5min which is a short incubation time [37] whereas 261 
protein G needed 30 min of incubation [38] and carcinoembryonic antigen was incubated 262 
for 45 min and 60 min with primary and secondary antibodies, respectively [39]. 263 
     Table 1 summarizes some of the analytical parameters of this CEIA method for MRP1 264 
determination.  Compared to the Western blot determination of P-glycoprotein in human 265 
colon adenocaranoma cells LS-180 [40], intraday variation in this work was comparable 266 
(7.1%), while the interday variation was better than the reported value (17.4%). while the 267 
linear range was better than that of competitive CEIA [31].  The LOD obtained was 268 
similar to 0.9 nM obtained by competitive CIEA CEIA [23], but higher than 5 × 10-12 M 269 
determined by noncompetitive IEF [24].  The lower LOD is observed in noncompetitive 270 
IEF because the method incorporates a concentration step.  It is worth noting that 271 
selectivity against other closely related MRPs like MRP2, MRP3 was not tested since the 272 
manufacturer of anti MRP1 antibody indicated that no cross reaction against other MRPs 273 
was expected. 274 
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     Like A549 cells [4, 35], RDES cells would be expected to express MRP1, since MRP1 275 
expression has been detected in myeloma samples [41].  Therefore, RDES cell lysates 276 
were reacted with labeled anti-MRP1.  Fig. 3 shows a typical separation of the antibody 277 
and its complex when using an RDES cell lysate as a sample.  Thus, similar to A549, 278 
RDES cells like A549, result indicates that, are capable of expressing can express MRP1. 279 
as well as. 280 
 281 
3.2. Determination of relative amounts of MRP1 in RDES and A549 cell lysates 282 
     The developed CEIA method was used to determine the relative amounts of MRP1 in 283 
A549 and RDES cancer cells.  As shown in Table 2, the relative amounts of MRP1 in the 284 
cells were measured after incubating the cells in DOX-free, DOX, and DOX/probenecid 285 
culture media for either 12 or 24 hours.  Probenecid, which is known to inhibit MRP1 286 
[42], was employed since it has been reported to enhanced the accumulation of 287 
anthracyclines in A549 and RDES cells [43].  The results show that both cell lines 288 
expressed MRP1, even in the absence of DOX, and that A549 contained more MRP1 289 
than RDES.  Lung tissues express several ABC proteins in order to prevent the 290 
accumulation of harmful xenobiotics from inhaled air [44].  MRP1, which is known to 291 
cause MDR in many lung tumors [4], is localized in the basolateral surface, where it 292 
protects the lung tissues against airborne xenobiotics.  Thus, even in the absence of DOX, 293 
A549 cells are expected to show relatively higher levels of MRP1 expression than RDES. 294 
     After treatment of cells with DOX for 12 h, the expression of MRP1 increased in both 295 
cell types, but to a different extents: RDES showed a greater increase (57%) than A549 296 
(29%), although the total amount was less than A549.  The levels of expression of MRP1 297 
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did not differ between exposures of 12 and 24 h to DOX in either A549 or RDES.  A 298 
nearly constant expression of MRP1 between the 12 h and 24 h incubation accompanied 299 
by decrease in DOX accumulation suggest that drug efflux can still occur provided that 300 
MRP1 has attained a certain level of expression.  Generally, these results are in 301 
agreement with previous works [45,46], in which anthracyclines, including DOX and 302 
epirubicin, were reported to induce MRP1 expression in lung cancer cells.  The MRP1 303 
expression of the cells treated with DOX was similar to that of the cells treated with 304 
DOX/probenecid with for 24 h incubation.  It is interesting to note that the cells treated 305 
with DOX/probenecid for 12 h showed a higher expression of MRP1 in 12 h than 24 h- 306 
incubation for both A549 and RDES.  This implies that MRP1 expression is also affected 307 
by inhibitors, although the reason for the observed down-regulation after 24 h treatment 308 
with DOX/probenecid is unknown.  Similar down-regulation of P-glycoprotein was 309 
observed in rat astrocytes with protracted treatment at a high concentration of DOX (500 310 
ng mL-1, 48 h) [47].  Therefore, a high concentration of a substrate for an ABC protein 311 
may induce up-regulation and subsequent down-regulation, although further investigation 312 
is necessary to clarify the mechanism involved. 313 
     To further evaluate the method, the relative amounts of MRP1 were compared with 314 
intracellular DOX concentration, in which the amount of DOX was determined using the 315 
same CE-LIF system and employing a previously developed method [34].  Several 316 
studies have shown that the expression of MRP1 lowers the sensitivity of the cells 317 
towards DOX [17 20, 48].  The lowered sensitivity to DOX would be induced by efflux 318 
of DOX through over-expressed MRP1.  Therefore, Tthe results of the present study are 319 
consistent with the aforementioned findings [17 20,48] since increase of MPR1 320 
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expression and reduction of DOX concentration were observed simultaneously when 321 
either A549 or RDES was treated with DOX upon incubation for 12 or 24 h (Table 2).  322 
However, the amounts of DOX that accumulated in the presence of probenecid, in both 323 
A549 and RDES, did not reflect an increase in MRP1 expression.  A similar observation 324 
was made by Rajagopal et al. [49] when they examined MRP1 activity using transient 325 
expression of fluorescently tagged MRP1.  This observation may be ascribed to 326 
probenecid being an MRP1 substrate, which is therefore effluxed at the expense of DOX.  327 
Thus, an increase in MRP1 causes a higher efflux in probenecid than in DOX, leading to 328 
a modest increase in the intracellular DOX concentration. 329 
 330 
4. Concluding remarks 331 
A CEIA-LIF method for relative quantification of MRP1 was developed.  The method 332 
is useful as a quick analytical tool for relative quantification of MRP1 by virtue of its 333 
simplicity, and shorter analysis timeand multianalytevariate analysis capability.  The 334 
method’s reliability has been demonstrated by the similarity of its results to those 335 
obtained by other established methods.  The present study also demonstrates that CEIA-336 
LIF can be used to separate higher-mass proteins (> 170 kDa), and, hence, can be used to 337 
investigate ABC and other superfamilies of proteins, which play crucial roles in cell 338 
activities.  Because of the method’s ability to measure the kinetics of complex formation, 339 
more comprehensive investigations of the rate of complexation can be designed to gain 340 
further understanding of how to control the functioning of transporter proteins. 341 
 342 
 343 
 344 
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Figure Captions 436 
Figure 1.  Formation of the immune complex at different incubation times:  (a) 0 min, (b) 437 
11 min, (c) 22 min, (d) 42 min, and (e) 62 min.  1, anti MRP1; 2, Immuno-complex; 3, 438 
fluorescein.  Sample: A549 cell lysate treated with DOX for 12 h, incubation temperature 439 
37 oC.  Conditions for electrophoresis are given in the text. 440 
 441 
Figure 2.  Kinetic curve of the immune complex formation.   Conditions are the same as 442 
for Figure 1. 443 
 444 
Figure 3.  The separation of anti-MRP1 and its immune complex.  1, anti-MRP1; 2, 445 
Immuno-complex; 3, fluorescein.  Sample: RDES cell lysate treated with DOX for 12 h, 446 
reaction time 60 min.  Other conditions are the same as in Figure 1. 447 
Table 1 
Analytical parameters of the CEIA-LIF method for MRP1 quantification. 
Cells/L (x 104) Precision (RSD, %) 
 Intraday Interday 
3.3 6.2 8.18 
6.6 5.9 7.16 
13.2 5.6 6.61 
 
n = 7, LOD (estimated from at S/N=3) = 0.1 0.2 nM , Linear range; 1.7 - 14.9 x 104 Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2 
The levels of MRP1 expression and the amount of accumulated DOX in cancer cells. 
Cell type  Treatment 
Relative amount of MRP1/ 
protein content (nmoles/ mg)
Amount of DOX/protein 
content (μmoles/ mg) 
A549 
F 38.2±1.2 76.4±2.4 0 
A-12 49.4±2.0 98.8±4.0 0.42 
A-24 47.0±1.6 94.0±3.2 0.26 
AI-12 71.8±2.9 144±5.8 0.99 
AI-24 45.0±1.6 90.0±3.2 -* 
    
RDES 
F 21.6±0.1 43.2±0.2 0 
A-12 34.0±1.5 68.0±3.0 1.15 
A-24 35.0±0.1 70.0±0.2 0.99 
AI-12 49.0±2.2 98.0±4.4 1.56 
AI-24 36.8±1.3 73.6±2.6 -* 
 
F, DOX free; A-12, 12 h incubation with DOX; A-24, 24 h incubation with DOX; AI-12, 
12 h incubation with DOX and probenecid; AI-24, 24 h incubation with DOX and 
probenecid. 
*Amounts of DOX were not determined for AI-24. 
 



